文献速递炎症性肠病

术前肿瘤坏死因子抑制剂暴露对炎症性肠病腹部手术患者安全性的前瞻性队列研究

Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery.
PubMed 文献 · Gastroenterology · 2022-04-10

多中心前瞻性观察研究纳入947例炎症性肠病腹部手术患者,其中382例术前12周内使用肿瘤坏死因子抑制剂。当前暴露与未暴露者的任何感染率(18.1% vs 20.2%)和手术部位感染率(12.0% vs 12.6%)相似,多变量分析显示当前暴露与任何感染(OR 1.050,95%CI 0.716-1.535)或手术部位感染(OR 1.249,95%CI 0.793-1.960)无关,可检测药物浓度亦无关联。

要点

  • 术前12周内使用肿瘤坏死因子抑制剂与术后30天内任何感染或手术部位感染风险无独立关联。
  • 当前暴露组与未暴露组的任何感染率分别为18.1%和20.2%,手术部位感染率分别为12.0%和12.6%。
  • 多变量分析中当前暴露与任何感染的OR为1.050(95%CI 0.716-1.535),与手术部位感染的OR为1.249(95%CI 0.793-1.960)。

核心结论

  • 术前肿瘤坏死因子抑制剂暴露与炎症性肠病腹部手术患者术后感染性并发症无关。

研究设计与样本

  • 多中心前瞻性观察研究,纳入来自克罗恩病与结肠炎基金会临床研究联盟17个中心的947例接受腹部手术的炎症性肠病患者,入组时间为2014年9月至2017年6月。

主要发现

  • 当前暴露于肿瘤坏死因子抑制剂的患者382例,其任何感染率为18.1%,未暴露者为20.2%(P = .469)。
  • 当前暴露组手术部位感染率为12.0%,未暴露组为12.6%(P = .889)。
  • 多变量分析中,当前暴露与任何感染无关联(OR 1.050,95%CI 0.716-1.535),与手术部位感染无关联(OR 1.249,95%CI 0.793-1.960)。
  • 可检测的肿瘤坏死因子抑制剂血清药物浓度与任何感染或手术部位感染无关。

关键数值与推荐

  • 当前肿瘤坏死因子抑制剂暴露定义为术前12周内使用。
  • 任何感染率:当前暴露组18.1% vs 未暴露组20.2%(P = .469)。
  • 手术部位感染率:当前暴露组12.0% vs 未暴露组12.6%(P = .889)。
  • 多变量模型中任何感染的OR为1.050(95%CI 0.716-1.535),手术部位感染的OR为1.249(95%CI 0.793-1.960)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Whether preoperative treatment of inflammatory bowel disease (IBD) with tumor necrosis factor inhibitors (TNFis) increases the risk of postoperative infectious complications remains controversial. The primary aim of this study was to determine whether preoperative exposure to TNFis is an independent risk factor for postoperative infectious complications within 30 days of surgery. METHODS: We conducted a multicenter prospective observational study of patients with IBD undergoing intra-abdominal surgery across 17 sites from the Crohn's & Colitis Foundation Clinical Research Alliance. Infectious complications were categorized as surgical site infections (SSIs) or non-SSIs. Current TNFi exposure was defined as use within 12 weeks of surgery, and serum was collected for drug-level analyses. Multivariable models for occurrence of the primary outcome, any infection, or SSI were adjusted by predefined covariates (age, sex, preoperative steroid use, and disease type), baseline variables significantly associated (P < .05) with any infection or SSI separately, and TNFi exposure status. Exploratory models used TNFi exposure based on serum drug concentration. RESULTS: A total of 947 patients were enrolled from September 2014 through June 2017. Current TNFi exposure was reported by 382 patients. Any infection (18.1% vs 20.2%, P = .469) and SSI (12.0% vs 12.6%, P = .889) rates were similar in patients currently exposed to TNFis and those unexposed. In multivariable analysis, current TNFi exposure was not associated with any infection (odds ratio, 1.050; 95% confidence interval, 0.716-1.535) or SSI (odds ratio, 1.249; 95% confidence interval, 0.793-1.960). Detectable TNFi drug concentration was not associated with any infection or SSI. CONCLUSIONS: Preoperative TNFi exposure was not associated with postoperative infectious complications in a large prospective multicenter cohort.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Cohen BL, Fleshner P, Kane SV, et al. Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery. Gastroenterology. 2022. PMID: 35413359. doi:10.1053/j.gastro.2022.03.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。